Evidence map›Paper›PMID 32319604›Full record

ArticleMolecular medicine reports2020

HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition.

Xiaojing Jia, Huien Wang, Zhongxin Li, Jing Yan, Yan Guo, Wujie Zhao, Lixia Gao, Bin Wang, Yitao Jia

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Integrative Evaluation ofMolecules (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.International journal of molecular sciences · 2021
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiaojing JiaDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Huien WangDepartment of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Zhongxin LiSecond Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
Jing YanDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Yan GuoFifth Department of Oncology, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei 050011, P.R. China.
Wujie ZhaoDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Lixia GaoDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Bin WangDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Yitao JiaDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Hebei General Hospital · CNFifth Hospital of Shijiazhuang · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains one of the most common cancer types worldwide. A few previous studies have examined whether HER4 may promote the progression of CRC. The present study examined the associations among the expression levels of members of the HER family, and investigated the potential mechanism underlying the function of HER4 in CRC cells. Immunohistochemistry analysis was conducted to detect the expression levels of HER family members in patients with CRC. HER4 expression was knocked down using short hairpin RNA in HCT116 cells, and confirmed by quantitative PCR and western blotting. The proliferation and adhesion of CRC cells were analyzed by CCK‑8 assays and adhesive assays, respectively. Flow cytometry was used to measure cell apoptosis. Western blotting and immunofluorescence staining in CRC cells were performed to identify proteins related to epithelial‑mesenchymal transition. The proportion of patients with CRC presenting positive expression of the HER family members epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 were 72.1, 45.2, 43.8 and 34.2%, respectively. No relationship was found between HER4 and EGFR, HER2 or HER3 expression. Higher expression of HER4 was positively associated with lymph node metastasis (P=0.039). In the present study, HER4 expression was found to be associated with an unfavorable clinical outcome in patients with CRC (Plogrank=0.020). Cell proliferation was inhibited, and apoptosis was increased following HER4 knockdown. Furthermore, HER4 knockdown increased the expression of E‑cadherin and decreased the expressions of N‑cadherin and vimentin (P<0.05). HER4 expression was found to be unrelated to other HER family members. In the present study, positive expression of HER4 promoted the progression of CRC through epithelial‑mesenchymal transition.

Indexed as

Disease ProgressionEpithelial-Mesenchymal TransitionAdultAgedAged, 80 and overCadherinsCell AdhesionCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleCadherinsERBB4 protein, humanReceptor, ErbB-4Vimentincolorectal cancerepithelial-mesenchymal transitionHer4metastasisprognosis

Identifiers

PMID32319604
PMCPMC7057779
OpenAlexW3004942458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.